Search results
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters· 4 days ago, opens new tab said on Wednesday its experimental gene therapy for Duchenne muscular dystrophy...
Springbok Analytics Announces Phase 1 Clinical Trial Evaluating Clenbuterol as FSHD Treatment
Williamson Daily News· 4 days agoSpringbok's MRI-based muscle analysis helps researchers to better understand and identify disease...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks· 4 days agoFree Report) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular dystrophy ...
Solid Biosciences Inc. (NASDAQ:SLDB) Receives $16.00 Consensus Price Target from Brokerages
ETF DAILY NEWS· 3 days agoSeveral research analysts have recently weighed in on SLDB shares. Piper Sandler began coverage on Solid Biosciences in a report on Friday, May 31st. William Blair reiterated an “outperform” ...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 3 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Susanna Gatti High Sells 40,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock
ETF DAILY NEWS· 2 days agoDyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) COO Susanna Gatti High sold 40,000 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, June 12th. Following ...
Northland family with young girl in wheelchair wins bathroom remodel giveaway
FOX 4 Kansas City· 2 days agoOlivia’s Big Splash, named in memory of Olivia Bloomfield who became an advocate for every child,...
Springbok Analytics Announces Phase 1 Clinical Trial Evaluating Clenbuterol as FSHD Treatment
The Tomahawk· 4 days agoSpringbok Analytics (www.springbokanalytics.com), a life sciences muscle analytics company, announced today its participation in a Phase 1 Clinical Trial to evaluate safe dosage for clenbuterol ...
Avidity Up 33% on Rare Muscle Disease Study Results - Arcutis Biotherapeutics (NASDAQ:ARQT), Heron...
Benzinga· 3 days agoAvidity Biosciences RNA announced encouraging initial data from the phase I/II FORTITUDE study...
Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Oxana Beskrovnaya Sells 2,136 Shares
ETF DAILY NEWS· 5 days agoDyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) insider Oxana Beskrovnaya sold 2,136 shares of Dyne Therapeutics stock in a transaction on Tuesday, June 11th. The stock was sold at an ...